陜西西岳制藥擁有25+獲批的原料藥批文和30+正在研發(fā)報(bào)批的三四類新藥，在渭南和寶雞設(shè)有兩個(gè)戰(zhàn)略生產(chǎn)基地，年產(chǎn)能超過2,000噸。作為一家集醫(yī)藥研發(fā)、生產(chǎn)、全球銷售于一體的綜合性企業(yè)，我們擁有ISO 9001/14001/45001/50001認(rèn)證的質(zhì)量體系，并提供完整的DMF文件以確保全球合規(guī)。我們提供廣泛的CDMO&CMO服務(wù)，結(jié)合定制化解決方案，確保為客戶提供全方位的支持。我們的綠色制造實(shí)踐包括超過85%的溶劑回收和超低液體排放，符合國(guó)際ESG標(biāo)準(zhǔn)。
With 25+ approved APIs and 30+ APIs under development, Shaanxi Xiyue Pharmaceutical operates two manufacture sites (Weinan & Baoji) manufacturing over 2,000MT annual capacity. As a vertically integrated enterprise spanning R&D, cGMP production, and global sales, we hold ISO 9001/14001/45001/50001 certifications and provide full DMF documentation for global compliance. Our comprehensive CDMO/CMO services, supported by tailor-made solutions, ensure end-to-end client support. Green manufacturing practices—including >85% solvent recovery and ultra-low liquid discharge—align with global ESG standards.
企業(yè)歷程 Milestone
1968年，西北第二合成藥廠創(chuàng)立---西北地區(qū)最大的合成制藥廠。
1968, Founded as the largest synthetic API drug manufacturer in Northwest China.
1992年，引進(jìn)港資，改名陜西西岳制藥有限公司---陜西省首家中外合資企業(yè)。
In 1992, Renamed as Shaanxi Xiyue Pharma, the first Sino-foreign JV company inShaanxi
2008年, 陜西海辰云和醫(yī)藥科技有限公司全資收購(gòu)陜西西岳制藥有限公司，改制而成一家集醫(yī)藥產(chǎn)業(yè)的研發(fā)、生產(chǎn)及銷售為一體的現(xiàn)代化高新技術(shù)企業(yè)
2008, Acquired by Haichen Yunhe Group -- modernized R&D-production-to-sales integration
2017年，成立陜西西岳制藥（扶風(fēng)）有限公司---聚焦五大產(chǎn)品管線: 降壓、降脂、降糖、消炎鎮(zhèn)痛、消化類
In 2017, Founded the second manufacture site ---Established Xiyue Pharma Fufeng-Focusing on five core Therapy areas: Anti-Hepotensive, Anti-Diabetic, Anti-Lipidemic, Anti-inflammatory/Analgesic, Digestive
2020年，組建了由博士作為學(xué)術(shù)帶頭人的三支研發(fā)團(tuán)隊(duì)
2020, Launched 3 Ph.D-led R&D Teams
現(xiàn)在，三十多個(gè)原料藥陸續(xù)落地
Currently, accelerating 30+ APIs toward commercialization
